More News! One third of FDA-approved drugs cause safety concerns

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Marco Diaz Segura
  • Dusseldorf spin-out NUMAFERM has secured seed financing to advance its bacteria-based peptide production platform.
Oleksii G
  • Nearly one third of drugs approved by the FDA cause concern for safety after entering the market
  • AB Science has received a request from a watchdog to suspend clinical trials for masitinib in mastocytosis until it complies with Good Clinical Practice standards
Brian Lasenby
  • Roman researchers have collaborated on a nano-slingshot to launch drugs into cells. If only there were videos!
  • Kite’s CAR-T program now has a patient death on its hands, caused by the same brain swelling that drove Juno to jettison its own program. Novartis is still in the lead

Images from Brian Lasenby, Eric Axelson, Marco Diaz Segura, Oleksii G / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.